Roth MKM downgraded Acer Therapeutics to Neutral from Buy with a $1.50 price target after the company entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACER:
- Acer Therapeutics (NASDAQ:ACER) Skyrockets 136% on Acquisition News
- Zevra Therapeutics to acquire Acer Therapeutics in potential $91M transaction
- Acer Therapeutics regains exclusive worldwide rights to OLPRUVA
- Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
- Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update